Crossmark

The optimal target of vancomycin area under the curve in early or later phase on clinical outcomes and nephrotoxicity in patients with enterococcal infective endocarditis: how much is enough?

Crossref DOI link: https://doi.org/10.1186/s12879-026-12993-5

Published Online: 2026-03-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Worrasan, Aimatchara

Pongchaidecha, Manat

Santimaleeworagun, Wichai
Funding

Funding for this research was provided by:

the Research and Creative Fund, Faculty of Pharmacy, Silpakorn University (Grant No. RGG 001/2568)
License Information

Text and Data Mining valid from 2026-03-07

Version of Record valid from 2026-04-14
More Information

Article History

Received: 23 October 2025

Accepted: 26 February 2026

First Online: 7 March 2026

Declarations

:

: Ethical approval was obtained from the Research Ethics Committee of the Central Chest Institute of Thailand (REC 008/2568). This study was conducted in accordance with the Declaration of Helsinki. The requirement for written informed consent was waived due to the retrospective design and anonymized data.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below